Epizyme Receives Orphan Drug Designation for Leukemia Med

 Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for EPZ-5676. Criteria for orphan drug designation requires that the product be intended for treatment of a rare disease or condition, classified as affecting fewer than 200,000 people in the United States.

https://epizyme.com/pdf/Orphan%20Drug%20Designation%20Release%20-%20DOT1L.pdf